» Articles » PMID: 36876238

Improvement in Hypertension Control Among Adults Seen in Federally Qualified Health Center Clinics in the Stroke Belt: Implementing a Program with a Dashboard and Process Metrics

Overview
Journal Health Equity
Specialty Health Services
Date 2023 Mar 6
PMID 36876238
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Attain 75% hypertension (HTN) control and improve racial equity in control with the American Medical Association Measure accurately, Act rapidly, Partner with patients blood pressure (AMA MAP BP™) quality improvement program, including a monthly dashboard and practice facilitation.

Methods: Eight federally qualified health center clinics from the HopeHealth network in South Carolina participated. Clinic staff received monthly practice facilitation guided by a dashboard with process metrics (measure [repeat BP when initial systolic ≥140 or diastolic ≥90 mmHg; Act [number antihypertensive medication classes prescribed at standard dose or greater to adults with uncontrolled BP]; Partner [follow-up within 30 days of uncontrolled BP; systolic BP fall after medication added]) and outcome metric (BP <140/<90). Electronic health record data were obtained on adults ≥18 years at baseline and monthly during MAP BP. Patients with diagnosed HTN, ≥1 encounter at baseline, and ≥2 encounters during 6 months of MAP BP were included in this evaluation.

Results: Among 45,498 adults with encounters during the 1-year baseline, 20,963 (46.1%) had diagnosed HTN; 12,370 (59%) met the inclusion criteria (67% black, 29% white; mean (standard deviation) age 59.5 (12.8) years; 16.3% uninsured. HTN control improved (63.6% vs. 75.1%, <0.0001), reflecting positive changes in Measure, Act, and Partner metrics (all <0.001), although control remained lower in non-Hispanic black than in non-Hispanic white adults (73.8% vs. 78.4%, <0.001).

Conclusions: With MAP BP, the HTN control goal was attained among adults eligible for analysis. Ongoing efforts aim to improve program access and racial equity in control.

Citing Articles

Trends in Blood Pressure Control among US Adults With Hypertension, 2013-2014 to 2021-2023.

Hardy S, Jaeger B, Foti K, Ghazi L, Wozniak G, Muntner P Am J Hypertens. 2024; 38(2):120-128.

PMID: 39504487 PMC: 11735471. DOI: 10.1093/ajh/hpae141.


Virtual practice facilitation as an implementation strategy for launching opioid safety committees for quality improvement in primary care: feasibility, acceptability, and intervention fidelity.

Mogk J, Allen C, Levitz C, Stefanik-Guizlo K, Bourcier E, Trapp Petty M BMC Prim Care. 2024; 25(1):384.

PMID: 39462338 PMC: 11515251. DOI: 10.1186/s12875-024-02632-w.


Development and usability of an EHR-driven hypertension disparities dashboard in primary care: A qualitative study.

Adediran E, Owens R, Gardner E, Lockrey A, Carlson E, Forbes D J Clin Hypertens (Greenwich). 2024; 26(7):797-805.

PMID: 38850400 PMC: 11232442. DOI: 10.1111/jch.14834.

References
1.
Cooper-DeHoff R, Fontil V, Carton T, Chamberlain A, Todd J, OBrien E . Tracking Blood Pressure Control Performance and Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control Laboratory. J Am Heart Assoc. 2021; 10(21):e022224. PMC: 8751828. DOI: 10.1161/JAHA.121.022224. View

2.
Berlowitz D, Ash A, HICKEY E, Friedman R, Glickman M, Kader B . Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998; 339(27):1957-63. DOI: 10.1056/NEJM199812313392701. View

3.
Perry H, Roccella E . Conference report on stroke mortality in the southeastern United States. Hypertension. 1998; 31(6):1206-15. DOI: 10.1161/01.hyp.31.6.1206. View

4.
Svetkey L, Moore T, Simons-Morton D, Appel L, Bray G, Sacks F . Angiotensinogen genotype and blood pressure response in the Dietary Approaches to Stop Hypertension (DASH) study. J Hypertens. 2001; 19(11):1949-56. DOI: 10.1097/00004872-200111000-00004. View

5.
Hunt S, Geleijnse J, Wu L, Witteman J, Williams R, Grobbee D . Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Am J Hypertens. 1999; 12(5):460-6. DOI: 10.1016/s0895-7061(99)00014-x. View